• Business combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed, innovative biopharmaceutical company focused on next-generation cancer therapies of novel bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs)
  • Strengthened financial position with $27.5 million principal amount senior secured note financing and $50 million share purchase agreement to advance VERAXA's pipeline of oncology drug candidates utilizing its novel BiTAC platform
  • VERAXA recently presented promising data supporting the underlying principle of its novel BiTAC platform technology at the American Association for Cancer Research (AACR) 2026 Annual Meeting
  • VERAXA's common stock and warrants to commence trading tomorrow on the Nasdaq Capital Market under the ticker symbols "VRXA" and "VRXAW", respectively

ZURICH, SWITZERLAND – June 10, 2026 -- VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, today announced that its previously announced business combination ("Business Combination") with Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager"))), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, was closed successfully (the "Closing"). Pursuant to the Closing, VERAXA Biotech AG and Voyager merged with and into VERAXA Biotech Holding AG, which will change its name to VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))). The shareholders of Voyager approved the transaction on March 12, 2026. The transaction had been previously approved by VERAXA's shareholders on February 27, 2026. Tomorrow, on June 11, 2026, VERAXA will commence trading its shares under the symbol "VRXA" and its warrants under the symbol "VRXAW" on the Nasdaq Capital Market.